Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04729387
Title Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals

peritoneum cancer

fallopian tube cancer

ovarian endometrial cancer

ovarian serous carcinoma


Pegylated liposomal-doxorubicin


Alpelisib + Olaparib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT

No variant requirements are available.